PEAK6 Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

PEAK6 Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-14,858	Closed	-$303K	–	4992
2016 Q1	$303K	Buy	+14,858	New	+$471K	﹤0.01%	2749
2015 Q4	–	Sell	-5,000	Closed	-$213K	–	5546
2015 Q3	$213K	Buy	+5,000	New	+$241K	﹤0.01%	3683
2013 Q3	–	Sell	-20,000	Closed	-$491	–	5658
2013 Q2	$491	Buy	+20,000	New	+$398K	﹤0.01%	2812

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Group's PTLA Position: Q2 2016 in Review

PEAK6 Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2016, closing a stake of 14,858 shares — an estimated $303K sold.

PEAK6 Group first reported a position in PTLA in Q2 2013 and held it in 3 quarters. The position peaked at $303K in Q1 2016. 159 funds tracked by Wall St. Rank hold PTLA as of Q2 2016.

PEAK6 Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
PEAK6 Group sold 14,858 Portola Pharmaceuticals, Inc. shares in Q2 2016, an estimated $303K.
PEAK6 Group first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
PEAK6 Group's Portola Pharmaceuticals, Inc. position peaked at $303K in Q1 2016.
159 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2016.

Based on PEAK6 Group's 13F filing for Q2 2016, filed 10 Aug 2016.